Avinger — IPO Roadshow (February 2018)
46 slides from Avinger's IPO roadshow presentation, Feb 5, 2018
Slide 1: Lumivascular Image Guided Therapy
LUMIVASCULAR IMAGE GUIDED THERAPY AVINGER
Slide 2: Safe Harbor
Safe Harbor AVINGER OVERVIEW 2017 PAGE 2 These slides and the accompanying oral presentation contain forward-looking statements about Avinger, Inc. (“Avinger” or the “Company”) and its business. All statements other than statements of historical fact contained in this presentation, including stateme
Slide 3: Free Writing Prospectus
FREE WRITING PROSPECTUS AVINGER OVERVIEW 2017 PAGE 3 This presentation highlights basic information about us and the offering. Because it is a summary that has been prepared solely for informational purposes, it does not contain all of the information that you should consider before investing in our
Slide 4: Unique and Differentiated Approach
4 UNIQUE AND DIFFERENTIATED APPROACH Lumivascular Platform is the only technology that combines real-time intravascular imaging with highly effective therapy for treatment of Peripheral Artery Disease (PAD) Over 21 million people projected to suffer from PAD in United States alone by 20201 COMPANY O
Slide 5: Lumivascular: Combining Real-Time Intravascular Imaging with Therapeutic Devices
LUMIVASCULAR adjestive : COMBINING REAL-TIME INTRAVASCULAR IMAGING WITH THERAPEUTIC DEVICES TO AVOID DAMAGING THE NATIVE ARTERY.
Slide 6: Lumivascular Approach: OCT Image-Guided Therapy vs Fluoroscopy
6 lumivascular approach OCT Image-guided therapy Fluoroscopy (X-Ray)
Slide 7: Arterial Damage Leads to Restenosis
Arterial Damage Leads to restenosis The external elastic lamina defines the border within the layers of the artery. Disrupting the external elastic lamina leads to accelerated restenosis. 7
Slide 8: Minimizing Damage to Adventitia
Minimizing damage to adventitia lumivascular Histopathological Evidence of Adventitial or Medial Injury is a Strong Predictor of Restenosis During Directional Atherectomy for Peripheral Artery Disease. J Endovasc Ther. 2015 Oct;22l5l:712-5. doi: 10.1177/1526602815597683. Epub 2015 Jul 24 FIH Data on
Slide 9: Lumivascular Platform
lumivascular platform only technology that offers real-time visualization of the inside of the artery during Peripheral Artery Disease (PAD) treatment 9 152 installed units FDA 510(k) cleared CE Mark Imaging console “RAZOR” Image-guided Atherectomy catheter Improved version (3.0) pending FDA 510(k)
Slide 10: Pipeline and Upcoming Milestones
Product Market Opportunity Expected FDA Clearance / Product Launch Commentary Pantheris 3.0 $280M ATK H1 2018 Next generation image guided atherectomy Pantheris 6F (BTK) “Below the Knee” $180M BTK H2 2018 Longer length, lower profile for BTK (below-the-knee) Ocelaris PAD $90M H1 2019 Next generation
Slide 11: Pantheris Lumivascular Atherectomy
PANTHERIS LUMIVASCULAR ATHERECTOMY
Slide 12: Lumivascular AT
LUMIVASCULAR AT
Slide 13: Pantheris: Visualization. Precision. Safety.
13 Pantheris Visualization. Precision. Safety. EEL Adventitia Media Balloon Middle Marker Balloon Disease Balloon EEL Media VISUALIZE the disease Cut with PRECISION Stay SAFE and don’t perforate
Slide 14: Competitive Positioning
Competitive positioning COMPANY PRODUCT MARKET SHARE APPROACH LUMINAL GAIN AVOIDS ADVENTITIA DISRUPTION REMOVAL OF PLAQUE RADIATION & CONTRAST SPARING IMAGING & VESSEL MEASUREMENT Avinger Pantheris <5% Directional Atherectomy Covidien / Medtronic SilverHawk 29% Directional Atherectomy CSI Diamondbac
Slide 15: Pantheris 3.0 – FDA 510(k) Submitted Q4 2017
Pantheris 3.0 – FDA 510(k) Submitted q4 2017 Product Specifications Currently in development at Avinger. Not available for sale 15 Petal Cutter Provides increased cutting efficiency and enhanced tissue engagement Redesigned Inflation System Single balloon for apposition and blood flow management Lon
Slide 16: Pantheris 6F (BTK) – FDA 510(k) Submission Planned
Pantheris 6F (BTK) – fda 510(K) SUBMISSION PLANNED Product Specifications Currently in development at Avinger. Not available for sale 16 Slimmer profile 140cm working length 1:1 torque transmission “Cobra” jog for apposition of cutter to tissue 3.5cm nosecone ENHANCEMENTS BENEFITS Compatible with 6F
Slide 17: Ocelot Lumivascular CTO Crossing
OCELOT LUMIVASCULAR CTO CROSSING
Slide 18: Ocelot Lumivascular CTO Crossing
18 ocelot Lumivascular Cto Crossing Bullet 1 Bullet 2 Bullet 3 Bullet 4 Bullet 5
Slide 19: Ocelaris: Next Generation CTO Crossing
Ocelaris: Next generation cto crossing 1000 RPM rotation speed generates Pantheris-like imaging and enhanced CTO crossability Low profile design allows for 5F sheath compatibility Variable angle tip deflection delivers precise maneuverability Anticipated Peripheral version H1 2019 Anticipated Corona
Slide 20: Commercial Drivers
commercial drivers Next Generation Products Pantheris 3.0 Ocelaris CTO Crosser (PAD) Lightbox L300 Platform New Product Initiatives Below-the-Knee Pantheris Atherectomy Catheter Ocelaris Coronary CTO Crosser Diagnostic Imaging Catheter for Peripheral and Coronary Coronary Atherectomy OCT Diagnostic
Slide 21: Lightbox L300 Platform
21 Lightbox L300 Platform Radically reduced footprint for easier lab integration Multiple system installation options Lab integrated option Cart-based option Variable speed catheter rotation (1,000 – 10,000 RPM) delivering enhanced OCT imaging and optimal device effectiveness Sterile field control s
Slide 22: OCT Diagnostic Reimbursement
Proposed Rule: new diagnostic imaging code/reimbursement for OCT in peripheral arteries (PAD) Incremental to already strong atherectomy procedural reimbursement Similar to existing intravascular ultrasound (IVUS) reimbursement Would apply to Ocelot, Pantheris and future OTC image-guided products Str
Slide 23: Clinical Data and Regulatory Programs
Label Expansion for In-Stent Restenosis (ISR) Lesions CE-Mark approval for ISR claim Sept 2017 FDA approval of IDE application for INSIGHT study April 2017 20 US/OUS Sites // up to 140 subjects 30-day follow-up for labeling safety claim; Follow-up will continue at 6 and 12 months Enrollment initiate
Slide 24: U.S. and International Sales Regions
U.S. and international sales regions 24 National Agreements Europe/Middle East Direct sales in Germany (1 Sales Director); sales through distributors in Switzerland, UAE and Turkey Japan Manufacturing facility registration with PMDA, Jan 2017 US Europe Japan China Regulatory Approval Process Initiat
Slide 25: Attractive and Growing Market
ATTRACTIVE and growing MARKET ($ in billions) U.S. PV Device Market is expected to be $3.6 billion in 2018 and expected to grow at a rate of 2.3% until 2023 U.S. PV DEVICE MARKET Treatment Procedures Market Size Amputations(1) 200,000 - Bypass(2) 160,000 - Surgical Procedures 360,000 - Stents(3) 314
Slide 26: Key 2018 Milestones
KEY 2018 milestones 26 Expected FDA clearance of Pantheris 3.0 – H1 2018 Anticipated filing of 510(k) for Pantheris BTK – mid-2018, with expected FDA clearance in H2 2018 Anticipated filing of CPT application for OCT diagnostic reimbursement – Q2 2018 Target completion of enrollment in ISR clinical
Slide 27: Key 2018 Milestones
KEY 2018 MILESTONES Expected FDA clearance of Pantheris 3.0 — H1 2018 Anticipated filing of 510(k) for Pantheris BTK — mid-2018, with expected FDA clearance in H2 2018 Anticipated filing of CPT application for OCT diagnostic reimbursement — Q2 2018 Target completion of enrollment in ISR clinical stu
Slide 28: CRG Partners Debt
28 CRG PARTNERS DEBT Balance As of December 31, 2017: $44.5 million CRG Partners has agreed to convert a significant portion of its secured debt into newly authorized non-voting convertible preferred stock. Conversion rate based on pricing of equity financing 19.99% cap and subject to shareholder vo
Slide 29: Financials
FINANCIALS 29 As of December 31, 2017 ($ in millions) LTM Revenue $9.9 Cash and Equivalents $5.4 * Cash Burn equals Net Change in Cash less Cash Flows from Financing $4.4 $3.0 $2.3 $1.6 1Q17A 2Q17A 3Q17A 4Q17A Avg Monthly Cash Burn * ($M)
Slide 30: Appendix
AVINGER OVERVIEW 2016 PAGE 30 PRESENTATION TITLE presentation Subtitle Bullet 1 Bullet 2 Bullet 3 Bullet 4 Bullet 5 APPENDIX
Slide 31: Management Team – Jeff Soinski
31 Management team Jeff Soinski – Chief Executive Officer Jeff Soinski has served as our President, Chief Executive Officer and a member of our Board of Directors since December 2014. From its formation in September 2009 until the acquisition of its Unisyn business by GE Healthcare in May 2013, Mr.
Slide 32: Management Team – Himanshu Patel
32 Management team Himanshu Patel – Chief Technology Officer Himanshu Patel has served as Chief Technology Officer of Avinger since its founding in 2007. Mr. Patel brings over 25 years of design experience developing medical devices, primarily for cardiovascular and peripheral artery disease treatme
Slide 33: Patent Overview
Patent overview As of December 31, 2017 42 U.S. patents and patent applications 17 allowed & issued US patents 25 pending utility applications 73 Ex-U.S. patents and patent applications 26 allowed & issued ex-US patents 41 Pending nationalized ex-US applications 6 pending PCT applications 115 Total
Slide 34: Patent Overview
AS OF DECEMBER 31, 2017 {0} PATENT OVERVIEW +» Avinger has an extensive IP portfolio covering key aspects of the design, manufacturing and therapeutic use of OCT imaging catheters, atherectomy devices and imaging console 42 U.S. patents and patent applications - 17 allowed & issued US patents — 25 p
Slide 35: Accurately Size BTK Vessels
Min Diameter = 4.2mm Max Diameter = 4.4mm Lumen Area = 14.4mm2 Min Diameter = 4.8mm Max Diameter = 5.0mm Lumen Area = 18.5mm2 PROXIMAL OVERLAP – TIGHTEST STENOSIS PROXIMAL OVERLAP – TIGHTEST STENOSIS OUTER STENT INNER STENT 35 Min Diameter = 4.2mm Max Diameter = 4.4mm Lumen Area = 16.mm2 ACCURATELY
Slide 36: VISION IDE Pantheris Clinical Data
36 VISIO N IDE PA N T H ER I S CL I N I CA L DA T A P AN T H E R I S 201 7 P AG E 21
Slide 37: Chronic Total Occlusion
CHRONIC TOTAL OCCLUSION 20% of Total Cohort Treated (N=33) Identical TLR rate of non-CTO cohort
Slide 38: Freedom from TLR by Lesion
24 MONTH OUTCOMES FREEDOM FROM TLR BY LESION Months since directional atherectomy with Pantheris catheter Freedom from TLR (%) 76% @ 24 months 83% @ 12 months 77% @ 18 months 38
Slide 39: Freedom from TLR by Patient
24 MONTH OUTCOMES FREEDOM FROM TLR BY PATIENT Months since directional atherectomy with Pantheris catheter 39 74% @ 24 months 75% @ 18 months 82% @ 12 months
Slide 40: CONNECT II Ocelot Clinical Data
40 Connect ii Ocelot clinical data Avinger’s CONNECT II is an FDA approved prospective, non-randomized, global clinical study that evaluated the safety and efficacy of the Ocelot System.
Slide 41: References
(1) Roguin et. al. AJC. May 2013. Vol.111(9): 1368-1372 (2) Vano et. al. Radiation Research. 2010.174(4): 490-495 (3) Ruso G. et. al. European Heart Journal. 2001 (4) Shope TB Radiographics. 1996. 16(5): 1195-9 (5) Segal E. et. al. JVS. 2013.58(6): 1556-62 AVINGER OVERVIEW 2017 PAGE 41
Slide 42: References
Staniloae, Cezar S., et al. "Endoluminal treatment of peripheral chronic total occlusions using the Crosser® recanalization catheter." Journal of Invasive Cardiology 23.9 (2011): 359 Laird, John R., et al. "Excimer laser with adjunctive balloon angioplasty and heparin-coated self-expanding stent gra
Slide 43: Zero Contrast and Reduced Radiation for CKD
Zero Contrast and Reduced Radiation For CKD (1) J. Invasive Cardiol. 2014 Aug; 26(8):363-9 43
Slide 44: Zero Contrast and Reduced Radiation for CKD
(3) ZERO CONTRAST AND REDUCED RADIATION FOR CKD Lumivascular 280mm SFA CTO 1} Constrast = OmL 2) Total Radiation = 0.3 Gy 2) DAP = 56.5 Gy-cm2 Endovascular’ Average 140mm SFA CTO 1) Constrast = 187.8 +/- 72mL 2) Radiation = 39.1 +/- 21.2 min 2) DAP = 210 +/- 212 Gy-cm2 @avinoer 300 228 187.0 56.5 0.
Slide 45: Wildcat CTO Crossing Catheter
i j LvoalmM © ‘The perfect balance of brains and brawn, Wildcat’s robust feel and 6 different modes make it the essential tool for crossing CTOs. EFFECTIVE INCROSSING CTOs —_JUICEBOX COMPATIBLE 89.3% crossing success rate, 95.2% safety rate, ‘Simpliies the procedure by providing powered tip rotation
Slide 46: Technical Specifications
TECHNICAL SPECIFICATIONS. j g i ZIVOALLIN©- {ts shapeable tip and 150cm in tength allows KC2 to go further. ‘SMALL PROFILE Maneuverable through small vessels with SF sheath. ‘SPIRAL FLUTES: Exposed spiral flutes with a gentler approach for lesion access. EXTRA, EXTRA LENGTH 150cm length offers exten